Sooma Depression Treatment

Care for depression made accessible

Depression is a worldwide public health problem that overwhelms millions of people across age groups and backgrounds – and most are still waiting in line to access care.

Sooma tDCS™ is an effective, safe, and scientifically proven brain stimulation-based depression treatment which has been EU MDR-certified for both in-clinic and at-home care. It’s a seamless solution that delivers better mental health to more patients in less time.

Developed in collaboration with clinicians

Sooma tDCS is a groundbreaking and proven effective brain stimulation treatment that has been developed in cooperation with leading university hospitals and health tech engineers.

As the first EU MDR-approved tDCS system for treating depression, Sooma tDCS is noninvasive and drug-free, and can be used either as a first line of treatment or to bring additive effects to other forms of treatment. By following a simple treatment protocol, most patients experience relief in their symptoms in as little as three weeks.

Care through an electric current

Sooma tDCS is based on transcranial direct current stimulation (tDCS), an innovative therapy that is backed by decades of research. It works through a small portable medical device, which is used in 30-minute sessions to safely deliver a mild electrical current to the area of the brain called the dorsolateral prefrontal cortex (DLPFC).

As a treatment method, tDCS is safe and is not associated with any serious adverse effects, as established in a safety review based on 33,000 stimulation sessions.* To ensure appropriate usage and monitor treatment progress, Sooma tDCS is always prescribed by a medical professional.

*Bikson M, Grossman P, Thomas C, Zannou AL, et al. Safety of Transcranial Direct Current Stimulation: Evidence Based Update 2016. Brain Stimul. 2016 Sep-Oct;9(5):641-661. doi: 10.1016/j.brs.2016.06.004.

Proven life-changing results

A leading clinical study on tDCS (2022) was conducted on 410 patient subjects – the largest study of its kind. The patients had been diagnosed with either moderate or severe depression and were treated with Sooma tDCS for an average of 3 weeks.

The results indicated a 55% response rate, i.e. that more than half of the patients experienced at least a 50% reduction in depressive symptoms at the end of the treatment period. The study further demonstrated that Sooma tDCS made it possible for a majority of the patients to overcome severe work impairment and get back to regular routines.*

* Lõokene M, Markov N, Nikander M, Neuvonen T, Dilkov D. Reduction of symptoms in patients with major depressive disorder after transcranial direct current stimulation treatment: A real-world study. Journal of Affective Disorders Reports, Volume 8, 2022. https://doi.org/10.1016/j.jadr.2022.100347.

Better mental health starts here

Whether you are a healthcare professional or a patient, find out how you can begin the journey towards improving mental health and care.